Arrowhead Pharmaceuticals
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell ARWR and other ETFs, options, and stocks.About ARWR
Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC.
CEOChristopher Richard Anzalone
CEOChristopher Richard Anzalone
Employees609
Employees609
HeadquartersPasadena, California
HeadquartersPasadena, California
Founded1989
Founded1989
Employees609
Employees609
ARWR Key Statistics
Market cap5.39B
Market cap5.39B
Price-Earnings ratio-30.85
Price-Earnings ratio-30.85
Dividend yield—
Dividend yield—
Average volume1.91M
Average volume1.91M
High today$40.29
High today$40.29
Low today$38.19
Low today$38.19
Open price$38.25
Open price$38.25
Volume2.59M
Volume2.59M
52 Week high$40.29
52 Week high$40.29
52 Week low$9.57
52 Week low$9.57
ARWR News
Simply Wall St 13h
Why Arrowhead Pharmaceuticals Is Up 5.9% After First-in-Class Dual Gene RNAi Trial FilingArrowhead Pharmaceuticals recently announced it has filed for regulatory clearance to begin a Phase 1/2a clinical trial of ARO-DIMER-PA, its novel RNAi therapy...
Analyst ratings
64%
of 14 ratingsBuy
64.3%
Hold
35.7%
Sell
0%
People also own
Based on the portfolios of people who own ARWR. This list is generated using Robinhood data, and it’s not a recommendation.